Fasting blood glucose to high-density lipoprotein cholesterol ratio and MASLD risk: non-linear association and BMI mediation in non-diabetic adults

空腹血糖与高密度脂蛋白胆固醇比值和MASLD风险:非糖尿病成人中的非线性关联和BMI介导作用

阅读:1

Abstract

BACKGROUND: The fasting blood glucose (FBG) to high-density lipoprotein cholesterol (HDL-C) ratio (GHR) integrates glucose and lipid metabolism, but its association with metabolic dysfunction-associated steatotic liver disease (MASLD) is unclear. We aimed to investigate the relationship between GHR and MASLD and to quantify the mediating role of body mass index (BMI) in non-diabetic adults. METHODS: This cross-sectional study included 13,682 non-diabetic Japanese adults from the NAGALA cohort (2004-2015). Logistic regression was used to examine the association between GHR and MASLD risk, while generalized additive models (GAMs) and smooth curve fitting were used to investigate their non-linear relationship. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic efficacy of GHR for MASLD, and mediation analysis was conducted to assess the mediating effect of BMI in this association. RESULTS: The prevalence of MASLD was 15.25% (n = 2,087). GHR was significantly higher in participants with MASLD (4.93 ± 1.14 vs. 3.59 ± 1.07). After multivariable adjustment, each 1-unit increase in GHR was associated with a 23% higher risk of MASLD (OR 1.23, 95% CI 1.15-1.31). A threshold effect was identified, with the risk escalating progressively when GHR < 4.62. GHR showed good discriminative ability with an AUC of 0.815 (95% CI: 0.806-0.824), significantly outperforming FBG alone (AUC 0.727) and HDL-C alone (AUC 0.787). Mediation analysis revealed that BMI accounted for 59.86% of the total association between GHR and MASLD risk as a potential intermediary factor. CONCLUSION: Among non-diabetic Japanese adults, elevated GHR is independently associated with an increased risk of MASLD, and BMI acts as a potential partial intermediary factor in this observed association. GHR may serve as a simple, cost-effective initial screening tool for MASLD in non-diabetic clinical practice, particularly in individuals without severe obesity or hypertriglyceridemia.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。